S&P 500   5,152.21 (-0.90%)
DOW   38,165.32 (-0.76%)
QQQ   440.38 (-1.12%)
AAPL   176.66 (+0.93%)
MSFT   423.89 (-0.94%)
META   516.81 (-1.21%)
GOOGL   158.50 (-0.57%)
AMZN   187.40 (-0.87%)
TSLA   172.75 (-1.06%)
NVDA   895.04 (-1.23%)
AMD   164.15 (-3.72%)
NIO   4.15 (-6.95%)
BABA   72.46 (-3.19%)
T   16.42 (+0.00%)
F   12.70 (-2.61%)
MU   123.54 (-3.11%)
GE   154.62 (-1.77%)
CGC   8.08 (-0.86%)
DIS   114.67 (-2.12%)
AMC   2.71 (-3.21%)
PFE   26.16 (-0.68%)
PYPL   65.25 (-0.84%)
XOM   122.10 (+0.25%)
S&P 500   5,152.21 (-0.90%)
DOW   38,165.32 (-0.76%)
QQQ   440.38 (-1.12%)
AAPL   176.66 (+0.93%)
MSFT   423.89 (-0.94%)
META   516.81 (-1.21%)
GOOGL   158.50 (-0.57%)
AMZN   187.40 (-0.87%)
TSLA   172.75 (-1.06%)
NVDA   895.04 (-1.23%)
AMD   164.15 (-3.72%)
NIO   4.15 (-6.95%)
BABA   72.46 (-3.19%)
T   16.42 (+0.00%)
F   12.70 (-2.61%)
MU   123.54 (-3.11%)
GE   154.62 (-1.77%)
CGC   8.08 (-0.86%)
DIS   114.67 (-2.12%)
AMC   2.71 (-3.21%)
PFE   26.16 (-0.68%)
PYPL   65.25 (-0.84%)
XOM   122.10 (+0.25%)
S&P 500   5,152.21 (-0.90%)
DOW   38,165.32 (-0.76%)
QQQ   440.38 (-1.12%)
AAPL   176.66 (+0.93%)
MSFT   423.89 (-0.94%)
META   516.81 (-1.21%)
GOOGL   158.50 (-0.57%)
AMZN   187.40 (-0.87%)
TSLA   172.75 (-1.06%)
NVDA   895.04 (-1.23%)
AMD   164.15 (-3.72%)
NIO   4.15 (-6.95%)
BABA   72.46 (-3.19%)
T   16.42 (+0.00%)
F   12.70 (-2.61%)
MU   123.54 (-3.11%)
GE   154.62 (-1.77%)
CGC   8.08 (-0.86%)
DIS   114.67 (-2.12%)
AMC   2.71 (-3.21%)
PFE   26.16 (-0.68%)
PYPL   65.25 (-0.84%)
XOM   122.10 (+0.25%)
S&P 500   5,152.21 (-0.90%)
DOW   38,165.32 (-0.76%)
QQQ   440.38 (-1.12%)
AAPL   176.66 (+0.93%)
MSFT   423.89 (-0.94%)
META   516.81 (-1.21%)
GOOGL   158.50 (-0.57%)
AMZN   187.40 (-0.87%)
TSLA   172.75 (-1.06%)
NVDA   895.04 (-1.23%)
AMD   164.15 (-3.72%)
NIO   4.15 (-6.95%)
BABA   72.46 (-3.19%)
T   16.42 (+0.00%)
F   12.70 (-2.61%)
MU   123.54 (-3.11%)
GE   154.62 (-1.77%)
CGC   8.08 (-0.86%)
DIS   114.67 (-2.12%)
AMC   2.71 (-3.21%)
PFE   26.16 (-0.68%)
PYPL   65.25 (-0.84%)
XOM   122.10 (+0.25%)
NASDAQ:LNTH

Lantheus (LNTH) Stock Price, News & Analysis

$60.39
-1.11 (-1.80%)
(As of 11:46 AM ET)
Today's Range
$60.24
$61.36
50-Day Range
$54.00
$68.26
52-Week Range
$50.20
$100.85
Volume
110,281 shs
Average Volume
1.07 million shs
Market Capitalization
$4.14 billion
P/E Ratio
13.02
Dividend Yield
N/A
Price Target
$104.14

Lantheus MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
71.5% Upside
$104.14 Price Target
Short Interest
Healthy
7.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
1.08mentions of Lantheus in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$57.41 M Bought Last Quarter
Proj. Earnings Growth
-3.67%
From $5.72 to $5.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.56 out of 5 stars

Medical Sector

256th out of 2,784 stocks

Diagnostic Substances Industry

7th out of 36 stocks

LNTH stock logo

About Lantheus Stock (NASDAQ:LNTH)

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

LNTH Stock Price History

LNTH Stock News Headlines

Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
LNTH Oct 2024 70.000 call
LNTH Oct 2024 80.000 call
LNTH Oct 2024 50.000 put
Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
Lantheus Holdings: Undervalued With A Good Outlook
LNTH Apr 2024 110.000 call
Assessing Lantheus Holdings: Insights From 4 Financial Analysts
LNTH Mar 2024 30.000 put
See More Headlines
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/12/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:LNTH
Employees
834
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$104.14
High Stock Price Target
$127.00
Low Stock Price Target
$82.00
Potential Upside/Downside
+71.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$326.66 million
Pretax Margin
31.70%

Debt

Sales & Book Value

Annual Sales
$1.30 billion
Cash Flow
$6.84 per share
Book Value
$11.91 per share

Miscellaneous

Free Float
67,523,000
Market Cap
$4.16 billion
Optionable
Optionable
Beta
0.53
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

LNTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LNTH shares.
View LNTH analyst ratings
or view top-rated stocks.

What is Lantheus' stock price target for 2024?

7 equities research analysts have issued twelve-month target prices for Lantheus' stock. Their LNTH share price targets range from $82.00 to $127.00. On average, they anticipate the company's stock price to reach $104.14 in the next twelve months. This suggests a possible upside of 71.5% from the stock's current price.
View analysts price targets for LNTH
or view top-rated stocks among Wall Street analysts.

How have LNTH shares performed in 2024?

Lantheus' stock was trading at $62.00 at the beginning of 2024. Since then, LNTH shares have decreased by 2.1% and is now trading at $60.72.
View the best growth stocks for 2024 here
.

When is Lantheus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LNTH earnings forecast
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, February, 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating analysts' consensus estimates of $1.33 by $0.26. The medical equipment provider earned $354 million during the quarter, compared to analysts' expectations of $350.44 million. Lantheus had a net margin of 25.20% and a trailing twelve-month return on equity of 63.16%.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus issued an update on its first quarter 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of 1.500-1.540 for the period, compared to the consensus earnings per share estimate of 1.510. The company issued revenue guidance of $347.0 million-$355.0 million, compared to the consensus revenue estimate of $336.4 million.

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?
When did Lantheus IPO?

Lantheus (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Who are Lantheus' major shareholders?

Lantheus' stock is owned by many different institutional and retail investors. Top institutional investors include Reinhart Partners LLC. (2.14%), Los Angeles Capital Management LLC (0.06%), Silverberg Bernstein Capital Management LLC (0.03%), Juncture Wealth Strategies LLC (0.01%), Clearview Wealth Advisors LLC (0.01%) and FCF Advisors LLC (0.01%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, John J Bolla, Lantheus Alpha Therapy, Llc, Mary Anne Heino, Michael P Duffy, Minnie Baylor-Henry, Paul Blanchfield and Robert J Jr Marshall.
View institutional ownership trends
.

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LNTH) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners